CapsulesClinical Overview
Rivastigmine is a pseudo-irreversible carbamate dual inhibitor of both acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) on the WHO Model List of Essential Medicines. It facilitates cholinergic transmission by delaying acetylcholine degradation, with dual enzyme inhibition providing sustained efficacy in advanced disease where BuChE activity increases. Indicated for mild-to-moderate dementia of the Alzheimer's type and mild-to-moderate dementia associated with Parkinson's disease.
Active Pharmaceutical Ingredients
Verified Clinical References
Usage Guidelines
Take orally twice daily with meals (morning and evening) with water to reduce cholinergic gastrointestinal adverse effects. Titrate slowly over several weeks.
General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.
Possible Side Effects
Common: Nausea, vomiting, anorexia, dyspepsia, weight loss, diarrhea, dizziness, headache. Rare/Severe: Severe vomiting with esophageal rupture, bradycardia, syncope, and peptic ulceration.
*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.
Precautions & Warnings
Transdermal patch reduces gastrointestinal side effects compared to oral capsules; ensure only one patch is worn at a time to prevent life-threatening cholinergic overdose. Vagotonic effects can cause bradycardia. Caution in asthma, COPD, and peptic ulcer disease.
Schedule H (Prescription Required)
This medication is scheduled under statutory drug regulatory frameworks (CDSCO / Drugs & Cosmetics Rules). Dispensing requires a valid medical prescription from a registered medical practitioner. Self-medication or unsupervised dosage adjustment carries significant clinical risks.
Medical Disclaimer: Statutory Clinical Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice, clinical diagnosis, or treatment recommendations. Always consult a registered medical practitioner or qualified pharmacist before initiating, modifying, or substituting any medication regimen.
Rivastigmine Capsules 3mg
Rivastigmine is a pseudo-irreversible carbamate dual inhibitor of both acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) on the WHO Model List of Essential Medicines. It facilitates cholinergic transmission by delaying acetylcholine degradation, with dual enzyme inhibition providing sustained efficacy in advanced disease where BuChE activity increases. Indicated for mild-to-moderate dementia of the Alzheimer's type and mild-to-moderate dementia associated with Parkinson's disease.
Rivastigmine Capsules 4.5 mg
Rivastigmine is a pseudo-irreversible carbamate dual inhibitor of both acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) on the WHO Model List of Essential Medicines. It facilitates cholinergic transmission by delaying acetylcholine degradation, with dual enzyme inhibition providing sustained efficacy in advanced disease where BuChE activity increases. Indicated for mild-to-moderate dementia of the Alzheimer's type and mild-to-moderate dementia associated with Parkinson's disease.
Rivastigmine Capsules 6 mg
Rivastigmine is a pseudo-irreversible carbamate dual inhibitor of both acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) on the WHO Model List of Essential Medicines. It facilitates cholinergic transmission by delaying acetylcholine degradation, with dual enzyme inhibition providing sustained efficacy in advanced disease where BuChE activity increases. Indicated for mild-to-moderate dementia of the Alzheimer's type and mild-to-moderate dementia associated with Parkinson's disease.
Rivastigmine Transdermal Patch 9mg (4.6mg/24 hour)
Rivastigmine is a pseudo-irreversible carbamate dual inhibitor of both acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) on the WHO Model List of Essential Medicines. It facilitates cholinergic transmission by delaying acetylcholine degradation, with dual enzyme inhibition providing sustained efficacy in advanced disease where BuChE activity increases. Indicated for mild-to-moderate dementia of the Alzheimer's type and mild-to-moderate dementia associated with Parkinson's disease.